{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:25:58Z","timestamp":1783783558050,"version":"3.55.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:sec>\n                    <jats:title>Background and Objective<\/jats:title>\n                    <jats:p>Non-alcoholic fatty liver disease (NAFLD) represents the most prevalent chronic hepatic metabolic disorder globally. Without timely intervention, it can progress to non-alcoholic steatohepatitis (NASH), liver fibrosis, and even hepatocellular carcinoma. Early detection and diagnosis are critical for disease management. metabolomics, a powerful tool for identifying diagnostic metabolic biomarkers of diseases, is frequently integrated with machine learning (ML) algorithms to improve analytical efficiency. This study aims to compare serum metabolomic profiles between NAFLD patients and healthy controls, identify differential metabolites, and employ machine learning algorithms to discover biomarkers with diagnostic value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study enrolled 26 healthy controls and 165 patients diagnosed with NAFLD via ultrasound, and performed serum untargeted metabolomics analysis. Specifically, metabolomics techniques were used to detect serum metabolites, while orthogonal partial least squares-discriminant analysis (OPLS-DA) was applied to screen for significantly differential metabolites between groups and conduct pathway enrichment analysis. In the ML phase, the dataset was split at an 8:2 ratio: 80% of the data (131 NAFLD cases and 21 healthy controls) was used for model training, and 20% (34 NAFLD cases and five healthy controls) served as an independent test set to validate model performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Metabolomic differential analysis identified 942 significantly differential metabolites (656 upregulated and 286 downregulated) between the NAFLD and healthy control groups, which were primarily enriched in caffeine metabolism, cholesterol metabolism, and the FoxO and AMPK signaling pathways. After training and validating machine learning models, serum metabolites maresin 1, canavaninosuccinate, paraxanthine, and 1-methyluric acid demonstrated robust diagnostic performance for NAFLD and can serve as independent predictive biomarkers, with 1-methyluric acid exhibiting the highest diagnostic contribution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Integration of untargeted metabolomics and machine learning effectively distinguishes NAFLD patients from healthy controls. cholesterol metabolism, caffeine metabolism, and the FoxO and AMPK signaling pathways may participate in NAFLD pathogenesis. ML-validated metabolites 1-methyluric acid, paraxanthine, canavaninosuccinate, and maresin one hold potential as diagnostic biomarkers and therapeutic targets for NAFLD, with 1-methyluric acid exhibiting the highest diagnostic relevance. In summary, serum metabolomics provides stable, accurate biomarkers for NAFLD early warning and diagnosis, and this study offers data and resource support for optimizing its clinical.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmolb.2026.1730023","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:34:49Z","timestamp":1770615289000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Serum biomarker screening and metabolic profiling analysis of nonalcoholic fatty liver disease patients using untargeted metabolomics and machine learning techniques"],"prefix":"10.3389","volume":"13","author":[{"given":"Lijuan","family":"Dan","sequence":"first","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Shi","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Cao","sequence":"additional","affiliation":[{"name":"School of Computer and Information Technology, Shanxi University","place":["Taiyuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyan","family":"Li","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirui","family":"Kong","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, West Area of The Third Affiliated Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojie","family":"You","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenping","family":"Liu","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Hao","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Song","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Mu","sequence":"additional","affiliation":[{"name":"Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"Li","sequence":"additional","affiliation":[{"name":"Clinical Laboratory, West Area of The Third Affiliated Hospital of Chengdu University of Traditional Chinese Medicine","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jhep.2012.05.019","article-title":"Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat-induced non-alcoholic steatohepatitis","volume":"57","author":"Abdelmegeed","year":"2012","journal-title":"J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.bbadis.2015.05.015","article-title":"Recent insights on the role of cholesterol in non-alcoholic fatty liver disease","volume":"1852","author":"Arguello","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"B3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1002\/hep.31599","article-title":"NAFLD: reporting histologic findings in clinical practice","volume":"73","author":"Brunt","year":"2021","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/s41591-022-01980-3","article-title":"Metabolomic profiles predict individual multidisease outcomes","volume":"28","author":"Buergel","year":"2022","journal-title":"Nat. Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"101052","DOI":"10.1016\/j.jpha.2024.101052","article-title":"Targeting AMPK related signaling pathways: a feasible approach for natural herbal medicines to intervene non-alcoholic fatty liver disease","volume":"15","author":"Cai","year":"2025","journal-title":"J. Pharm. Anal."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cld.1061","article-title":"Global epidemiology of chronic liver disease","volume":"17","author":"Cheemerla","year":"2021","journal-title":"Clin. Liver Dis. Hob."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/nu15010004","article-title":"Increased intake of both caffeine and non-caffeine coffee components is associated with reduced NAFLD severity in subjects with type 2 diabetes","volume":"15","author":"Coelho","year":"2022","journal-title":"Nutrients"},{"key":"B11","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2337\/dc13-1203","article-title":"Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis","volume":"37","author":"Ding","year":"2014","journal-title":"Diabetes Care"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00011-023-01732-0","article-title":"The combination of machine learning and untargeted metabolomics identifies the lipid metabolism -related gene CH25H as a potential biomarker in asthma","volume":"72","author":"Ding","year":"2023","journal-title":"Inflamm. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2013.11.001","article-title":"Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease","volume":"146","author":"Dumas","year":"2014","journal-title":"Gastroenterology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/antiox12030554","article-title":"Anti-Inflammatory effect of caffeine on muscle under lipopolysaccharide-induced inflammation","volume":"12","author":"Eichwald","year":"2023","journal-title":"Antioxidants (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ebiom.2018.04.009","article-title":"Activation of liver AMPK with PF-06409577 corrects NAFLD and lowers cholesterol in rodent and primate preclinical models","volume":"31","author":"Esquejo","year":"2018","journal-title":"EBioMedicine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J. Hepatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.celrep.2018.12.036","article-title":"Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD","volume":"26","author":"Garcia","year":"2019","journal-title":"Cell Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1878-5085-3-14","article-title":"General report and recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive","volume":"3","author":"Golubnitschaja","year":"2012","journal-title":"Prev. Personalised Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13167-015-0030-6","article-title":"EPMA position paper in cancer: current overview and future perspectives","volume":"6","author":"Grech","year":"2015","journal-title":"EPMA J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1002\/anie.200905579","article-title":"Targeted metabolomics for biomarker discovery","volume":"49","author":"Griffiths","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B21","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/HEP.0000000000000307","article-title":"p16 INK4A drives nonalcoholic fatty liver disease phenotypes in high fat diet fed mice through biliary E2F1\/FOXO1\/IGF-1 signaling","volume":"78","author":"Kundu","year":"2023","journal-title":"Hepatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1242\/jcs.051011","article-title":"mTOR signaling at a glance","volume":"122","author":"Laplante","year":"2009","journal-title":"J. Cell Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s0009-8981(00)00201-1","article-title":"Antioxidant ability of caffeine and its metabolites based on the study of oxygen radical absorbing capacity and inhibition of LDL peroxidation","volume":"295","author":"Lee","year":"2000","journal-title":"Clin. Chim. Acta"},{"key":"B24","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.plipres.2017.04.002","article-title":"A global perspective on FOXO1 in lipid metabolism and lipid-related diseases","volume":"66","author":"Li","year":"2017","journal-title":"Prog. Lipid Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"101109","DOI":"10.1016\/j.plipres.2021.101109","article-title":"Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis","volume":"83","author":"Li","year":"2021","journal-title":"Prog. Lipid Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41580-019-0190-7","article-title":"Mechanisms and regulation of cholesterol homeostasis","volume":"21","author":"Luo","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"4304376","DOI":"10.1155\/2018\/4304376","article-title":"Application of machine learning techniques for clinical predictive modeling: a cross-sectional Study on nonalcoholic Fatty liver disease in China","volume":"2018","author":"Ma","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21080979","article-title":"Coffee consumption and oxidative stress: a review of human intervention studies","volume":"21","author":"Martini","year":"2016","journal-title":"Molecules"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1172\/JCI27047","article-title":"Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism","volume":"116","author":"Matsumoto","year":"2006","journal-title":"J. Clin. Invest"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19072034","article-title":"New aspects of lipotoxicity in nonalcoholic steatohepatitis","volume":"19","author":"Mendez-Sanchez","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/hep.24731","article-title":"Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis","volume":"55","author":"Molloy","year":"2012","journal-title":"Hepatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"154320","DOI":"10.1016\/j.metabol.2020.154320","article-title":"The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease","author":"Perakakis","year":"2020","journal-title":"Metabolism"},{"key":"B33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40168-021-01221-8","article-title":"A multi-omics approach unravels metagenomic and metabolic alterations of a probiotic and synbiotic additive in rainbow trout (Oncorhynchus mykiss)","volume":"10","author":"Rasmussen","year":"2022","journal-title":"Microbiome"},{"key":"B34","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3109\/10715762.2013.788167","article-title":"Inhibition of radical-induced DNA strand breaks by water-soluble constituents of coffee: phenolics and caffeine metabolites","volume":"47","author":"Rathod","year":"2013","journal-title":"Free Radic. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-Gomez","year":"2017","journal-title":"J. Hepatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41419-023-06177-1","article-title":"FOXO family isoforms","volume":"14","author":"Santos","year":"2023","journal-title":"Cell Death Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1053\/j.gastro.2014.10.005","article-title":"Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort","volume":"148","author":"Setiawan","year":"2015","journal-title":"Gastroenterology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/art.41733","article-title":"Serum Metabolomics Identifies dysregulated pathways and potential metabolic biomarkers for hyperuricemia and gout","volume":"73","author":"Shen","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B39","volume-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource","year":"2016"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort","volume":"70","author":"Simon","year":"2021","journal-title":"Gut"},{"key":"B41","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.apsb.2022.10.003","article-title":"Synergistic activation of AMPK by AdipoR1\/2 agonist and inhibitor of EDPs-EBP interaction recover NAFLD through enhancing mitochondrial function in mice","volume":"13","author":"Song","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"B42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41580-022-00547-x","article-title":"New insights into activation and function of the AMPK","volume":"24","author":"Steinberg","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"107155","DOI":"10.1016\/j.phrs.2024.107155","article-title":"SIRT1: harnessing multiple pathways to hinder NAFLD","volume":"203","author":"Tian","year":"2024","journal-title":"Pharmacol. Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00281-009-0152-9","article-title":"The immunopathogenesis of alcoholic and nonalcoholic steatohepatitis: two triggers for one disease?","volume":"31","author":"Valenti","year":"2009","journal-title":"Semin. Immunopathol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1021\/pr2009252","article-title":"Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry","volume":"11","author":"Wang","year":"2012","journal-title":"J. Proteome Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1186\/s12967-024-05315-3","article-title":"An novel effective and safe model for the diagnosis of nonalcoholic fatty liver disease in China: gene excavations, clinical validations, and mechanism elucidation","volume":"22","author":"Wang","year":"2024","journal-title":"J. Transl. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nprot.2012.135","article-title":"Global metabolic profiling of animal and human tissues via UPLC-MS","volume":"8","author":"Want","year":"2013","journal-title":"Nat. Protoc."},{"key":"B48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.cmpb.2018.12.032","article-title":"Prediction of fatty liver disease using machine learning algorithms","volume":"170","author":"Wu","year":"2019","journal-title":"Comput. Methods Programs Biomed."},{"key":"B49","doi-asserted-by":"publisher","first-page":"103499","DOI":"10.1016\/j.redox.2025.103499","article-title":"Caffeine ameliorates metabolic-associated steatohepatitis by rescuing hepatic Dusp9","volume":"80","author":"Xin","year":"2025","journal-title":"Redox Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"155264","DOI":"10.1016\/j.metabol.2022.155264","article-title":"Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: an overview and current perspectives","volume":"134","author":"Yan","year":"2022","journal-title":"Metabolism"},{"key":"B51","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/hep.30198","article-title":"Dual-Specificity phosphatase 9 protects against Nonalcoholic Fatty liver disease in mice through ASK1 suppression","volume":"69","author":"Ye","year":"2019","journal-title":"Hepatology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jhep.2021.08.019","article-title":"Substantial gaps in evaluation and treatment of patients with hepatitis B in the US","volume":"76","author":"Ye","year":"2022","journal-title":"J. Hepatol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1021\/ac8019366","article-title":"Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum","volume":"81","author":"Zelena","year":"2009","journal-title":"Anal. Chem."},{"key":"B55","doi-asserted-by":"publisher","first-page":"106724","DOI":"10.1016\/j.compbiomed.2023.106724","article-title":"Identification of potential feature genes in non-alcoholic fatty liver disease using bioinformatics analysis and machine learning strategies","volume":"157","author":"Zhang","year":"2023","journal-title":"Comput. Biol. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1126\/science.aay0542","article-title":"An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis","volume":"367","author":"Zhao","year":"2020","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological Features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1730023\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:34:51Z","timestamp":1770615291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1730023\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":57,"alternative-id":["10.3389\/fmolb.2026.1730023"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2026.1730023","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"article-number":"1730023"}}